
Mesna Injection
Form: Injection
Strength: 100 mg/mL
Reference Brands: Mesnex(US)
Category: Blood Disorder
Mesna injection, marketed as Mesnex, is approved in the US by the FDA and in the EU via EMA to prevent hemorrhagic cystitis during chemotherapy. Regulatory approval requires a detailed dossier including clinical efficacy, safety data, manufacturing standards, and pharmacovigilance plans. In the US, the FDA conducts a comprehensive review, while the EMA assesses compliance with regional safety and quality standards. For guidance on dossier preparation, regulatory pathways, and successful market access, visit PharmaTradz. Ensuring regulatory compliance is essential for the safe, effective, and timely approval of mesna injection worldwide, supporting optimal patient care in oncology treatments.
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Related Products
Anti-Inhibitor Coagulant Complex (AICC) Lyophilized Powder
Strength: 500 units, 1000 units, and 2500 units
Form: Lyophilized Powder (Reconstituted for IV infusion)
Reference Brands: FEIBA(US)
View Details Get EnquiryProthrombin Complex Concentrate (PCC) injection
Strength: 250 IU to 300 IU
Form: Injection
Reference Brands: Kcentra (4-factor PCC), Bebulin VH (3-factor PCC)(US)
View Details Get EnquiryLeucovorin tablets/Capsule
Strength: 15 mg, 50 mg
Form: Tablet/Capsules
Reference Brands: Folvite(US & EU)
View Details Get EnquiryPegfilgrastim injection
Strength: 6 mg per single-use syringe
Form: Injection
Reference Brands: Neulasta, Pelgraz(US)
View Details Get Enquiry